United States: FDA Continues To Address Opioid Abuse

The Centers for Disease Control and Prevention (CDC) reports that "[t]he United States is in the midst of an opioid overdose epidemic," noting that the rate of overdose deaths involving opioids has nearly quadrupled in the last 15 years.1 Concomitant with this increase in overdoses has been a four-fold increase in opioid prescriptions.2 Many efforts are underway to alleviate the problem, including actions by CDC, various state legislatures, the Joint Commission, the Federation of State Medical Boards and the US Food and Drug Administration (FDA).

FDA has recently undertaken an additional series of steps to address opioid abuse. In February the agency issued an action plan calling for a "sweeping review" of its opioid policies. In March FDA began formally implementing some of these action items with required class-wide safety labeling changes for immediate-release (IR) opioids.3 And at about the same time, FDA also issued a new draft guidance document to support industry in developing generic opioids with abuse-deterrent formulations (ADF), ensuring that they are no less abuse-deterrent than the corresponding brand-name drug.4 FDA's stated goal is to reverse the opioid-abuse epidemic while still providing patients with access to effective pain relief.

Opioids Action Plan

In introducing the FDA Opioids Action Plan,5 the agency stated that it "is deeply concerned about the growing epidemic of opioid abuse, dependence and overdose in the United States" and that this is "a comprehensive action plan to take concrete steps toward reducing the impact of opioid abuse on American families and communities." As part of the Action Plan, the agency's actions will include the following:

  • Expanding use of advisory committees and experts, particularly for approving new opioids without abuse-deterrent properties and pediatric use;
  • Developing warnings and safety information for IR opioid labeling to provide doctors with better information about the risks of opioids and how to prescribe them safely;
  • Strengthening post-market requirements to gather better evidence on issues such as the serious risks of misuse and abuse associated with long-term use of opioids and predictors of opioid addiction;
  • Updating the Risk Evaluation and Mitigation Strategy (REMS) Program for opioids to increase the number of prescribers who receive training on pain management and to inform on the safe, appropriate prescribing of opioid drugs;
  • Expanding access to ADFs to discourage opioid abuse and encourage generic ADF product development;
  • Improving access to naloxone and overdose treatment, encouraging safer prescribing and use of opioids and ultimately developing new classes of pain medicines without the same risks as opioids; and
  • Reassessing the risk-benefit approval framework for opioids to formally incorporate broader public health considerations of abuse in approval decisions.

Opioid Labeling Changes

Less than two months after announcing its Action Plan, FDA announced required class-wide safety labeling changes for IR opioid pain medications.6 The new labeling requirements include a boxed warning about the serious risks of misuse, abuse, addiction, overdose and death, as well as a maternal use warning. FDA also updated the indication for IR opioid products, clarifying that these products should be reserved for severe pain with no acceptable alternative treatments. The dosing information is now more specific and includes patient monitoring instructions. FDA is additionally requiring for all opioid products safety labeling changes that provide additional information about the risks associated with opioids and encourage prescribers to balance those risks when managing patients' pain. These requirements supplement FDA's 2013 class-wide safety labeling changes and its then-new post-market study requirements for all extended-release and long-acting (ER/LA) opioid analgesics intended to treat pain.7

Draft Guidance on Generic Opioids

Finally, in its latest action to address the opioid abuse epidemic, FDA issued a draft guidance, "General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products,"8 to encourage industry to develop opioid products that are more difficult to abuse and also to ensure that generic ADF opioids are no less abuse-deterrent than their reference brand-name drugs. The draft guidance includes recommendations for studies generic drug manufacturers should conduct to demonstrate parity between the generic and brand-name product with respect to all potential routes of abuse (e.g. crushing and dissolving). The agency also acknowledged that more generic ADF opioids would improve access to abuse-deterrent opioids by lowering their cost. The public may submit comments to FDA on the document by May 24, 2016. In addition, FDA plans to schedule a public meeting on this issue later in the year to solicit feedback from outside experts and the public before finalizing the guidance.


FDA is among a growing number of agencies and organizations that are mobilizing to address, and hopefully ameliorate, the problem of opioid abuse and overdose. CDC statistics show that, concomitant with the quadruple increase in opioid overdose over the past 15 years, the amount of prescription opioids sold in the United States has nearly quadrupled during that same time.9 CDC has undertaken a number of broad steps to address the problem, including improving data quality and prevention strategies, strengthening state efforts at effective interventions and equipping health care providers with better data and tools to improve opioid prescribing. Focusing on the medications themselves and related approvals and labeling, the latest measures by FDA are another step forward in the battle against opioid abuse. Public comments may be submitted to FDA regarding the draft guidance on generic opioids by May 24, 2016.



Originally published on 13 April 2016

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2016. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions